Wantai Bio Pharm | Sustainability Performance
Develops, manufactures, and supplies diagnostic tests and vaccine products.
1991
China
1,001 - 5,000 employees
Medical Device
$100M - 500M in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9325
Overallⓘ#567
in Chinaⓘ#144
in Medical DeviceⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Nature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG Impact
Critical
Aligned
Controversy level
- Beijing Wantai Biological Pharmacy Enterprise Co (Shanghai-listed 603392.SH, Chinese diagnostics and vaccine maker, Zhong Shanshan (Nongfu Spring founder, China's richest man) controlled, first Chinese-developed HPV vaccine (Cecolin) maker) has faced sustained scrutiny over the contested 2023 to 2025 sustained Chinese HPV vaccine price war and collapse in Cecolin bivalent HPV vaccine sales (Wantai's HPV vaccine revenue fell sharply amid Chinese government-procurement price pressure and 9-valent competition), plus sustained scrutiny over Zhong Shanshan controlling shareholder governance complexity affecting Wantai institutional minority shareholders amid Chinese vaccine sector regulatory pressure.
